相关实验视频
Updated: Jan 7, 2026

03:20
Studying Chronic Exposure of Mice to Ultraviolet B Radiation
Published on: August 19, 2025
1.8K
窄带UVB可能会恢复慢性斑块牛皮患者的阿达利木马布疗效:一项前性探索性队列研究
Inês Tribolet de Abreu1,2, René Santus3, João Ferreira4
1Dermatology Department, Unidade Local de Saúde Santa Maria, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal. ines.tribolet.abreu@gmail.com.
概括
将窄带紫外线B (NB-UVB) 光疗添加到阿达利木马布治疗中,帮助大多数牛皮患者在失去对生物治疗的反应后恢复皮肤清除. 这种组合疗法显示了持续的结果,并且耐受性很好,提供了可行的治疗选择.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 照相医疗 (photomedicine) 是一种医学.
背景情况:
- 生物疗法 (BT) 已经改变了牛皮的治疗方法,但二次治疗失败很常见.
- 狭带紫外线B (NB-UVB) 光疗是一种具有免疫调节作用的已知局部治疗方法.
- 对于将NB-UVB与BT相结合的证据有限,特别是对于阿达利穆马布的失败.
研究的目的:
- 调查慢性斑块牛皮症患者的辅助NB-UVB光疗的疗效和安全性,这些患者经历了对阿达利木马布的二次反应丧失.
- 评估通过联合治疗恢复阿达利穆马布的疗效和减少疾病负担.
主要方法:
- 对11名患有牛皮和阿达利穆马布失败的成年人进行前性探索性队列研究 (没有抗阿达利穆马布抗体).
- 患者接受了NB-UVB光疗 (3次/周,25-30次),同时继续接受阿达利姆巴 (40毫克每两周一次).
- 牛皮区域和严重程度指数 (PASI) 和皮肤病生活质量指数 (DLQI) 用于评估.
主要成果:
- 辅助NB-UVB显著降低了平均PASI,从发作时的11.8降至6.2 (p=0.006).
- 五名患者 (45.5%) 实现了PASI 50,两名 (18.2%) 实现了PASI 75,持续响应≥24个月.
- DLQI从14.7显著改善到5.6 (p=0.005),表明疾病负担减少. NB-UVB的耐受性很好. 这是一个很好的结果.
结论:
- 辅助的NB-UVB光疗可以恢复二次治疗失败的患者的阿达利木马布疗效.
- 这种组合为管理牛皮提供了一种安全,可访问和具有成本效益的策略.
- 需要进一步的受控研究来确认疗效,并确定这种组合治疗的作用.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
413
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
413
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
447
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
447

